Soft Touch Breast Implants at DermSA

Only Natrelle® does gummy like this

Three cohesivities. Countless possibilities

Artistry becomes reality with the most complete portfolio of cohesive gel breast implants.

The implant you select is critical

The right implant can provide the upper pole fullness and contouring needed based on the desired breast shape.

The amount of upper pole fullness and contouring you need depends on available tissue.

The amount of upper pole fullness and contouring an implant has depends on its cohesivity. No two women are alike—from the amount of tissue they have to their breast-shaping needs. Your artistic vision relies on your ability to shape the breasts. Make your vision a reality with Natrelle®.
Different Breast Illustration
 

Designed for the shape you envision

With the Natrelle® Cohesive Collection, you can shape your breasts based on their varying levels of available tissue coverage.

Three cohesivities. Countless possibilities.

Natrelle® offers the widest range of cohesivities for every breast, patient type, and aesthetic vision — whether it’s a reconstruction, revision, or augmentation.5

3 Different Implants Illustration
 

Designed to maintain upper pole fullness***

All Natrelle INSPIRA® Breast Implants are designed for upper pole fullness. How well that fullness is maintained when held upright depends on the implant’s cohesivity.

Natrelle® Gel Breast Implants maintained upper pole fullness.(6,†)

***Based on implant performance testing. Clinical significance has not been established.

Natrelle Gel Implants upper pole fullness Illustration  
 

Designed for contouring that lasts(7*)

7* Based on implant performance testing. Clinical significance has not been established. Cohesivity determines how well an implant keeps its overall shape. An implant with highly cohesive gel will hold its contour more than an implant with responsive gel.(6,†)

Take creative control with 3 levels of cohesivity.

 

A shell that protects

Safety matters—from the outside in. The cohesive gel in Natrelle ® Gel breast implants is surrounded by a patented shell technology and a unique barrier layer.(7)

Natrelle® knows safety is important—that’s why Allergan has been evaluating the long-term safety and effectiveness of Natrelle® silicone-filled breast implants in patients since 1999.(7)

Take Creative Control with 3 Levels of Cohesivity Graphic comparison  
 

A shell that protects

Safety matters—from the outside in. The cohesive gel in Natrelle ® Gel breast implants is surrounded by a patented shell technology and a unique barrier layer.(7) Natrelle® knows safety is important—that’s why Allergan has been evaluating the long-term safety and effectiveness of Natrelle® silicone-filled breast implants in patients since 1999.(7)

Safety Soft Implant Shell That Protects Diagram  
 

A gel that stays

Cohesive gel in all Natrelle® Gel breast implants is designed to hold together.

When Natrelle® Gel implants are cut ex vivo and compressed, the gel moves back into the shell.

 
Hold Together Natrelle Implants Comparison Inspira Hold together Natrelle Implants Comparison Soft Touch Hold Together Natrelle Implants Comparison INSPIRA Cohesive

*Images for visual representation only. In vivo significance has not been established.

&nbsp

A more cohesive soft touch breast implant — what reconstruction you may need

PRIMARY Reconstruction Before and After Natrelle 410

*Implant selected: Natrelle ® 410 Style FF Implant dimensions: 475 cc volume, 13.5 cm base width, 14.0 cm height, 5.3 cm projection Photos provided by Dr Patricia McGuire. Individual results may vary.

“My patient is happy with her look—and that’s after 7 years. The highly cohesive gel in Natrelle® 410 makes a difference.” – Dr Patricia McGuire

Natrelle ® 410 with highly cohesive gel has low wrinkling/rippling rates: 6.2% in primary reconstruction patients through 10 years (n = 225).(8)

Now, the highly cohesive gel of Natrelle® 410 is available in a round gel.

REVISION Reconstruction Before and After Natrelle INSPIRA Cohesive

*Implant selected: Natrelle INSPIRA® Cohesive Style TCM-405 Implant dimensions: 405 cc volume, 13.25 cm diameter, 4.4 cm projection. Photos provided by Dr Alex N. Mesbahi. Individual results may vary.

“This patient came to me for a revision reconstruction and had very visible wrinkling/rippling. I could not have achieved these results without a more cohesive breast implant.” – Dr Alex N. Mesbahi PRIMARY Reconstruction Before and After Natrelle INSPIRA Cohesive

* Implant selected: Natrelle INSPIRA® Cohesive Style SCF-560. Implant dimensions: 560 cc volume, 13.50 cm diameter, 5.7 cm projection. Photos provided by Dr Mark L. Venturi. Individual results may vary.

“My patient needed an implant designed for upper pole fullness—Natrelle INSPIRA® Cohesive delivered.” Dr Mark L. Venturi

Look and feel—what augmentation patients say they want most(9,*)

PRIMARY Augmentation Before and After Natrelle 410 Cohesive

Implant selected: Natrelle ® 410 Style FM-395 Implant dimensions: 395 cc volume, 13.0 cm base width, 13.5 cm height, 4.8 cm projection Photos provided by Dr Bradley P. Bengtson. Individual results may vary.

“I wanted to look like me—just with more volume.” – Patient 96% of primary augmentation patients were satisfied through 10 years with Natrelle ® 410 (n = 292).(8) Augmentation Before and After Natrelle INSPIRA Cohesive

Implant selected: Natrelle INSPIRA® Cohesive Style SCM-310 Implant dimensions: 310 cc volume, 12.00 cm diameter, 4.0 cm projection Photos provided by Dr Allen Gabriel. Individual results may vary.

“My breasts looked deflated after having kids. Now they have a full, contoured look that I love.” – Patient PRIMARY Augmentation Before and After Natrelle INSPIRA Soft Touch

Implant selected: Natrelle INSPIRA® Soft Touch Style TSM-345 Implant dimensions: 345 cc volume, 12.50 cm diameter, 4.2 cm projection Photos provided by Dr Charles Randquist. Individual results may vary.

“I wanted fullness—especially at the top of my breasts. I’m so happy with my results.” – Patient

Shaping the future with you

Natrelle® is the #1 plastic surgery portfolio.10,11,*,†

Natrelle INSPIRA® Collection

#1 selected round gel implant collection in the US.10,*

Natrelle® 410

#1 selected anatomical implant in the US.11,†

Natrelle® 133 Series

#1 selected tissue expander in the US.11,†

Natrelle INSPIRA® Cohesive

Most cohesive round gel breast implant in the US.5

*Based on surgeon survey data, December 2016 (N = 100). †Based on US market share data through November 2016 (N = 67).

From Allergan—the leader in medical aesthetics.  
Natrelle® Breast Implants Important Information INDICATIONS Natrelle® Breast Implants are indicated for women for the following:
  • Breast augmentation for women at least 22 years old for silicone-filled implants. Breast augmentation for women at least 18 years old for saline-filled implants. Breast augmentation includes primary breast augmentation to increase breast size, as well as revision surgery to correct or improve the result of a primary breast augmentation surgery.
  • Breast reconstruction. Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the result of a primary breast reconstruction surgery.
† Methodology Breast implant gel was measured for material properties using the BTC-2000 ™. The BTC-2000 ™ applies a controlled vacuum, or negative pressure, to the gel while measuring the dynamic response of material deformation using a synchronized target laser. The gel for each device (n = 8 per group) was tested at 3 sites, all at or near the apex of the implant (anterior side). From those measurements, the gel cohesivity was calculated and the relative change was determined. 6,† Methodology Breast implant devices (n = 6 per group) were placed in a horizontal orientation on a sliding stage; the width and maximum projections of the implants were measured using fixed calipers. The devices were then placed in a vertical-supported orientation using a 90º angle, and the width and maximum projections were measured again. From those measurements, the retention of dimension was calculated and the relative change was determined. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Breast implant surgery should not be performed in:
  • Women with active infection anywhere in their body.
  • Women with existing cancer or precancer of their breast who have not received adequate treatment for those conditions.
  • Women who are currently pregnant or nursing.
WARNINGS
  • Breast implants are not lifetime devices or necessarily a one-time surgery.
  • Avoid damage during surgery: Care should be taken to avoid the use of excessive force and to minimize handling of the implant. Use care when using surgical instruments in proximity with the breast implant. For more information, please see the full Directions for Use.
PRECAUTIONS Safety and effectiveness have not been established in patients with the following:
  • Autoimmune diseases (eg, lupus and scleroderma).
  • A compromised immune system (eg, currently receiving immunosuppressive therapy).
  • Planned chemotherapy following breast implant placement.
  • Planned radiation therapy to the breast following breast implant placement.
  • Conditions or medications that interfere with wound healing and blood clotting.
  • Reduced blood supply to breast tissue.
  • Clinical diagnosis of depression or other mental health disorders, including body dysmorphic disorder and eating disorders. Please discuss any history of mental health disorders prior to surgery. Patients with a diagnosis of depression, or other mental health disorders, should wait until resolution or stabilization of these conditions prior to undergoing breast implantation surgery.
ADVERSE EVENTS Key adverse events are reoperation, implant removal with or without replacement, implant rupture with silicone-filled implants, implant deflation with saline-filled implants, and capsular contracture Baker Grade III/IV. Other potential adverse events that may occur with breast implant surgery include: asymmetry, breast pain, breast/skin sensation changes, capsular calcification, delayed wound healing, hematoma, hypertrophic scarring/scarring, implant extrusion, implant malposition, implant palpability/visibility, infection, nipple complications, redness, seroma, swelling, tissue/skin necrosis, wrinkling/rippling. For more information see the full Directions for Use at www.allergan.com/labeling/usa.htm. To report a problem with Natrelle® Breast Implants, please call Allergan at 1-800-433-8871. Natrelle® Breast Implants are available by prescription only. Natrelle INSPIRA® Natrelle INSPIRA® Soft Touch Natrelle INSPIRA® Cohesive Natrelle® 410 *Based on implant performance testing. Clinical significance has not been established. 5 Natrelle ® 133Plus and 133 Tissue Expanders With/Without Suture Tabs and With MAGNA-SITE® Injection Sites Important Information INDICATIONS Natrelle ® 133Plus and 133 Tissue Expanders are indicated for:
  • Breast reconstruction following mastectomy.
  • Treatment of underdeveloped breasts.
  • Treatment of soft tissue deformities.
CONTRAINDICATIONS
  • Who have an active infection or a residual gross tumor at the expansion site.
  • Undergoing adjuvant radiation therapy.
  • Whose physiological condition (eg, sensitive over- or underlying anatomy, obesity, smoking, diabetes, autoimmune disease, hypertension, chronic lung or severe cardiovascular disease, or osteogenesis imperfecta) or use of certain drugs (including those that interfere with blood clotting or affect tissue viability) poses an unduly high risk of surgical and/or postoperative complications.
  • Who are psychologically unsuitable.
WARNINGS
    • DO NOT alter the tissue expander or use adulterated fill. Fill only with sterile saline for injection as described in INSTRUCTIONS FOR USE. DO NOT expose to contaminants.
    • DO NOT expand if the pressure will compromise wound healing or vasculature of overlying tissue, or beyond patient or tissue tolerance.
Stop filling immediately if tissue damage, wound dehiscence, abnormal skin pallor, erythema, edema, pain, or tenderness are observed.
  • Active infection anywhere may increase risk of periprosthetic infection. Postoperative infections should be treated aggressively. Unresponsive or necrotizing infection may require premature removal.
PRECAUTIONS Active infections may need to be treated and resolved before surgery. Allergan relies on the surgeon to know and follow proper surgical procedures and carefully evaluate patient suitability using standard practice and individual experience. Avoid damage to the tissue expander and use a sterile backup in case of damage. Pay careful attention to tissue tolerance and hemostasis during surgery. Expansion should proceed moderately and never beyond patient or tissue tolerance. Avoid contamination in any postoperative procedure. WARNINGS
  • DO NOT use Natrelle ® 133Plus and 133 Tissue Expanders in patients who already have implanted devices that would be affected by a magnetic field (see Contraindications), because the MAGNA-SITE® integrated injection site contains a strong rare-earth, permanent magnet. Diagnostic testing with Magnetic Resonance Imaging (MRI) is contraindicated in patients with Natrelle ® 133Plus and 133 Tissue Expanders in place. Please see additional Natrelle ® 133Plus and 133 Tissue Expanders Important Safety Information on following pages.
  • Natrelle ® 133Plus and 133 Tissue Expanders are temporary, single-use only devices, and are not to be used for permanent implantation or beyond 6 months. Tissue expansion in breast reconstruction typically requires 4 months to 6 months.
  • When using suturing tabs be careful to avoid piercing the shell. Use a new one if damage occurs. Please see additional Natrelle ® 133Plus and 133 Tissue Expanders Important Safety Information on back.
ADVERSE REACTIONS Deflation, tissue damage, infection, extrusion, hematoma/seroma, capsular contracture, premature explantation, displacement, effects on bone, pain, sensation, distortion, inadequate tissue flap, and inflammatory reaction. For more information, please visit www.allergan.com/labeling/usa.htm. To report a problem with Natrelle ®, please call Allergan at 1-800-433-8871. Natrelle ® 133Plus and 133 Tissue Expanders are available by prescription only. References: 1. Data on file, Allergan, January 2017; Allergan Plastic Surgery Order Form. 2. More of Everything: Natrelle ® Product Catalog. Irvine, CA: Allergan; 2015. 3. Our products: breast implants. Mentor Worldwide LLC website. http://www.mentorwwllc.com /global-us/Breast.aspx. Updated April 2016. Accessed February 13, 2017. 4. Sientra ® HSC & HSC+ Breast Implant Product Catalog. Santa Barbara, CA: Sientra, Inc., 2015. http://sientra.com/Content/pdfs/MDC-0177%20R2%20HSCHSC%2B%20Breast%20Implants%20Product%20Catalog.pdf. Accessed February 13, 2017. 5. Data on file, Allergan, February 8, 2017; Study Report MD16075-DV2. 6. Data on file, Allergan, February 3, 2017; Study Report MD16075-DV1. 7. Natrelle ® Silicone-Filled Breast Implants and Natrelle INSPIRA® Breast Implants: Smooth & BIOCELL® Texture Directions for Use, 2016. 8. Natrelle ® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants Directions for Use, 2014. 9. Data on file, Allergan, March 2016; Plastic Surgery A&Us: PLS and Patients. 10. Data on file, Allergan, December 2016; Plastic Surgery Monthly Tracker: Breast Implants & Tissue Expanders. 11. Data on file, Allergan, November 2016; Breast Implant + Tissue Expander Share Tracker. 12. Kline & Company, Inc. Professional Skin Care: US Market Analysis and Opportunities. Parsippany, NJ: Kline & Company, Inc.; January 19, 2017. 13. Data on file, Allergan, 2016; EAME Brand Share. 14. Data on file, Allergan, February 2016; US Neurotoxin Market Share Report.